PMID- 31637101
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191024
IS  - 2162-1918 (Print)
IS  - 2162-1934 (Electronic)
IS  - 2162-1918 (Linking)
VI  - 8
IP  - 11
DP  - 2019 Nov 1
TI  - Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and 
      Cryopreserved Placental Membranes Containing Viable Cells.
PG  - 546-554
LID - 10.1089/wound.2019.1028 [doi]
AB  - Objective: To evaluate the clinical outcomes of lyopreserved placental membrane 
      containing viable cells (vLPM) in the treatment of nonhealing wounds of various 
      etiologies, and to compare them to those previously reported for cryopreserved 
      placental membrane containing viable cells (vCPM). Approach: Patients with 
      nonhealing wounds who qualified to receive advanced wound therapies were 
      consecutively enrolled and treated weekly with vLPM plus standard of care (SOC) 
      at five centers. Data were de-identified and retrospectively analyzed. Outcomes 
      included closure, time to closure, number of vLPM applications, and adverse 
      events (AEs). Results: Seventy-eight patients with 98 wounds (41 diabetic foot 
      ulcers [DFUs], 19 venous leg ulcers [VLUs], 10 surgical, and 28 others) with an 
      average size of 13.3 cm(2) and 8.7 months duration were treated. Fifty-eight of 
      the 98 wounds (59.2%) achieved complete closure with median time to closure of 63 
      days and 6 vLPM applications. The closure by wound etiology was 63% for DFUs, 47% 
      for VLUs, 70% for surgical wounds, and 57% for other types of wounds. Similar 
      closure rates have been previously demonstrated for vCPM. Wound duration was the 
      main predictor of closure: 65.8% versus 30.0% (p = 0.004) closure was achieved 
      for wounds of </=12 and >12 months duration, respectively. There were no AEs 
      related to vLPM application. Innovation: This is the first multicenter case 
      series evaluating the clinical outcomes of vLPM in a real-world setting. 
      Conclusion: These results support clinical equivalency between the two placental 
      membrane formulations with the added convenience of room-temperature storage for 
      vLPM, allowing it to be used in any wound-care setting.
CI  - (c) Charles E. Ananian, et al. 2019; Published by Mary Ann Liebert, Inc.
FAU - Ananian, Charles E
AU  - Ananian CE
AD  - New Hope Podiatry, Los Angeles, California.
FAU - Davis, R Daniel
AU  - Davis RD
AD  - Family Podiatry Center, Bridgeport, Connecticut.
FAU - Johnson, Eric L
AU  - Johnson EL
AD  - Bozeman Health Deaconess Hospital, Wound and Hyperbaric Center, Bozeman, Montana.
FAU - Regulski, Matthew J
AU  - Regulski MJ
AD  - Ocean County Foot & Ankle Surgical Associates, P.C., Forked River, New Jersey.
FAU - Reyzelman, Alexander M
AU  - Reyzelman AM
AD  - California School of Podiatric Medicine at Samuel Merritt University, Oakland, 
      California.
FAU - Saunders, Molly C
AU  - Saunders MC
AD  - Osiris Therapeutics, Inc., Columbia, Maryland.
FAU - Danilkovitch, Alla
AU  - Danilkovitch A
AD  - Osiris Therapeutics, Inc., Columbia, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20191016
PL  - United States
TA  - Adv Wound Care (New Rochelle)
JT  - Advances in wound care
JID - 101590593
PMC - PMC6798798
OTO - NOTNLM
OT  - lyopreserved
OT  - nonhealing
OT  - placental membrane
OT  - viable
OT  - wound
EDAT- 2019/10/23 06:00
MHDA- 2019/10/23 06:01
PMCR- 2019/10/16
CRDT- 2019/10/23 06:00
PHST- 2019/05/23 00:00 [received]
PHST- 2019/07/03 00:00 [accepted]
PHST- 2019/10/23 06:00 [entrez]
PHST- 2019/10/23 06:00 [pubmed]
PHST- 2019/10/23 06:01 [medline]
PHST- 2019/10/16 00:00 [pmc-release]
AID - 10.1089/wound.2019.1028 [pii]
AID - 10.1089/wound.2019.1028 [doi]
PST - ppublish
SO  - Adv Wound Care (New Rochelle). 2019 Nov 1;8(11):546-554. doi: 
      10.1089/wound.2019.1028. Epub 2019 Oct 16.